{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Irinotecan Hydrochloride is a generic chemotherapy drug used to treat certain cancers, such as colorectal cancer. It works by inhibiting cancer cell growth and is administered intravenously as an injection. Available in strengths like 20 mg/mL, it's a prescription medication manufactured by companies like Xiromed LLC. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Irinotecan hydrochloide \u2014 ANDA 212993 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212993", "mediaType": "text/html", "title": "Irinotecan hydrochloide"}], "identifier": "ANDA212993", "issued": "2016-09-16", "keyword": ["drug-information", "drug", "public-health", "medications", "prescription-drugs"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Irinotecan hydrochloide"}